Skip to main content
Have a personal or library account? Click to login
Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid Cover

Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid

Radiology and Oncology
Volume 47 (2013): Issue 3 (September 2013)
By:  and    
Open Access
|Jul 2013
References

References

  1. 1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies.2001;165-76.
    Open DOISearch in Google Scholar
  2. 2. Rajer M, Kovač V. Malignant spinal cord compression.2008;23-31.
    Open DOISearch in Google Scholar
  3. 3. Gojkovič Horvat A, Kovač V, Strojan P. Radiotherapy in palliative treatment of painful bone metastases.2009;213-24.
    Search in Google Scholar
  4. 4. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma.1999;1219-22.
    Open DOISearch in Google Scholar
  5. 5. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer.2000;181-6.
    Search in Google Scholar
  6. 6. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.2002;1458-68.
    Open DOISearch in Google Scholar
  7. 7. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.2004;879-82.
    Open DOISearch in Google Scholar
  8. 8. Aapro M, Saad F. Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.2012;85-101.
    Open DOISearch in Google Scholar
  9. 9. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.2011;572-83.
    Open DOISearch in Google Scholar
  10. 10. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Steven Devine S, et al. NCCN Guidelines version 1.2013. Multiple Myeloma.2013;11-7.
    Open DOISearch in Google Scholar
  11. 11. Tamburrelli FC, Proietti L, Scaramuzzo L, De Stefano V, Logroscino CA. Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report.2012;S141-5.
    Open DOISearch in Google Scholar
  12. 12. Mhaskar R, Redzepovic J, Wheatley K, Clark OAC, Miladinovic B, Glasmacher A, et al. Bisphosphonates in multiple myeloma: a network meta-analysis.2012;CD003188.
    Open DOISearch in Google Scholar
  13. 13. Mohler, JL, Armstrong AJ, Bahnson RR, Boston B, Busby EJ, D’Amico AV, et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.2012;1081-7
    Open DOISearch in Google Scholar
  14. 14. NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4 data files. Availabele 15th February, 2013: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
    Search in Google Scholar
  15. 15. Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME. Denosumab in patients with cancer and skeletal metastases: a systematic review and metaanalysis.2013;97-104.
    Open DOISearch in Google Scholar
  16. 16. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.2011;813-22.
    Open DOISearch in Google Scholar
  17. 17. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.2011;1125-32.
    Open DOISearch in Google Scholar
  18. 18. Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FLA, et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and metaanalysis.2012;36-44.
    Open DOISearch in Google Scholar
  19. 19. Polascik TJ, Given RW, Metzger C, Julian SR, Vestal JC, Karlin GS, et al. Openlabel trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.2005;1054-9.
    Open DOISearch in Google Scholar
  20. 20. Pouessel D, Culine S. Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.2012; 23: 141-2.
    Open DOISearch in Google Scholar
  21. 21. Coleman R, Cook R, Hirsh V, Major P, Lipton A. Zoledronic acid use in cancer patients: more than just supportive care?2011;11-23.
    Search in Google Scholar
DOI: https://doi.org/10.2478/raon-2013-0041 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 289 - 295
Published on: Jul 30, 2013
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
diphosphonates,
pain,
neoplasm metastasis,
bone,
clinical trial,
phase IV
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2013 Andrej Kmetec, Tine Hajdinjak, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 47 (2013): Issue 3 (September 2013)
Previous article
Next article